An appreciation from the out-going editor-in-chief Seigo Kinuya Editorial 22 November 2019 Pages: 875 - 876
From the respective expert viewpoints of the ANM specialty editors Masayuki InubushiMiho ShidaharaYasushi Kiyono Invited Review Article Open access 19 November 2019 Pages: 877 - 880
Comparisons of 131I-rituximab treatment responses in patients with aggressive lymphoma and indolent lymphoma Inki LeeByung Hyun ByunSang Moo Lim Original Article 30 September 2019 Pages: 881 - 890
PSMA SPECT/CT with 99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels Christian SchmidkonzTheresa Ida GoetzMichael Cordes Original Article 09 September 2019 Pages: 891 - 898
The evaluation of left ventricular dyssynchrony in hypertensive patients with a preserved systolic function undergoing gated SPECT myocardial perfusion imaging Maryam AlvandiZahra ShaghaghiZahra Sanaei Original Article 25 September 2019 Pages: 899 - 906
Association between carotid 18F-NaF and 18F-FDG uptake on PET/CT with ischemic vascular brain disease on MRI in patients with carotid artery disease Kengo FujimotoTakashi NorikaneYoshihiro Nishiyama Original Article 30 September 2019 Pages: 907 - 915
Correction of head movement by frame-to-frame image realignment for receptor imaging in positron emission tomography studies with [11C]raclopride and [11C]FLB 457 Yoko IkomaYasuyuki KimuraTetsuya Suhara Original Article 11 October 2019 Pages: 916 - 929
Potential prognostic implications of myocardial thallium-201 and iodine-123-beta-methylpentadecanoic acid dual scintigraphy in patients with Anderson–Fabry disease Tomoaki HagaTakahiro OkumuraToyoaki Murohara Original Article 11 October 2019 Pages: 930 - 936
Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer Sara PellegrinoRosa FontiSilvana Del Vecchio Original Article 14 October 2019 Pages: 937 - 944
Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients Nicolas PlouznikoffCarlos ArtigasPatrick Flamen Short Communication 05 October 2019 Pages: 945 - 954
